FINWIRES · TerminalLIVE
FINWIRES

Telix Pharmaceuticals Upsizes Convertible Notes Due 2031 to $600 Million

By

Telix Pharmaceuticals (ASX:TLX) successfully priced and upsized its 1.50% convertible notes due 2031 to $600 million from $550 million, issued through its wholly owned subsidiary, Telix Pharmaceuticals Investments, reflecting strong investor demand, according to a Wednesday Australian bourse filing.

The notes can be converted into the company's ordinary shares at an initial conversion price of $13.85, which reflects a premium of around 38% over the reference share price, per the filing.

The bonds pay interest quarterly and mature around April 2031, unless they are redeemed or converted earlier, the filing said.

The company will simultaneously repurchase and cancel over 85% of its 2029 convertible bonds through a reverse bookbuild process, with settlement for both transactions expected on April 22, the filing added.

Related Articles

Asia

Farglory Land Development OKs NT$3.8 Billion Construction Project

Farglory Land Development (TPE:5522) approved a NT$3.8 billion construction contract for a project in Tainan's East District, according to a Monday Taiwan Exchange filing.Shares slid over 1% in Tuesday's late morning trade.The contract involves a joint venture to develop land in the Dongguang Section, with work to be carried out by its unit, Farglory Construction.The project is expected to support future revenue growth upon completion.The company did not disclose a timeline for the project.

TPE:5522
Asia

China Northern Rare Earth Forecasts Up to 118% Rise in Q1 Profit; Shares Fall 4%

China Northern Rare Earth (SHA:600111) expects attributable profit to jump 109% to 118% to between 900 million yuan and 940 million yuan in the first quarter from 430.6 million yuan in the year-ago period, according to a Tuesday filing with the Shanghai bourse.The upbeat forecast is attributable to a price increase in rare earths, as well as cost reduction and risk control, the filing said.Shares fell 4% during the midday break.

SHA:600111
Asia

Sinomach's 2025 Profit Slips 7%, Revenue Jumps 14%; Shares Up 5%

Sinomach Precision Industry's (SHE:002046) net profit attributable to shareholders in 2025 slipped 7% to 260.3 million yuan from 279.8 million yuan a year earlier, according to a Shenzhen bourse filing on Tuesday.Earnings per share fell 8% year on year to 0.49 yuan from 0.53 yuan.Operating revenue jumped 14% to 3.02 billion yuan from 2.66 billion yuan in the previous year.The Chinese industrial equipment manufacturer's shares jumped 5% during the morning trade.

SHE:002046